Identification and validation of a five-lncRNA signature for predicting survival with targeted drug candidates in ovarian cancer.

Identification and validation of a five-lncRNA signature for predicting survival with targeted drug candidates in ovarian cancer.
复制标题

鉴定和验证五长链非编码RNA特征,用于预测卵巢癌候选靶向药物的生存率

DOI:
10.1080/21655979.2021.1946632
复制
发表时间:
2021-12
期刊:
影响因子:
4.9
通讯作者:
Zhou X
Zhou X
中科院分区:
生物学2区
文献类型:
--
作者:
Lin N;Lin JZ;Tanaka Y;Sun P;Zhou X

文献摘要

参考文献

被引文献

相似文献

摘要 长链非编码 RNA (lncRNA) 的失调在卵巢癌 (OC) 中发挥着至关重要的作用。在本研究中,我们基于TCGA和GTEx RNA-seq数据库,利用Kaplan-Meier分析和单变量Cox、LASSO和多变量Cox筛选出OC和正常卵巢之间5种差异表达的lncRNA(AC092718.4、AC138035.1、BMPR1B-DT、RNF157-AS1和TPT1-AS1) 回归。然后,构建风险特征,通过ROC曲线确认1年、3年、5年生存预测的准确性,并提供在线生存计算器以方便临床使用。随着lncRNA-microRNA-mRNA调控网络的建立,进行了基因本体论(GO)和京都基因和基因组百科全书(KEGG)分析,表明多种癌症相关功能和途径的参与。最后,通过Connectivity Map预测了5种候选小分子药物(硫利达嗪、三氟拉嗪、洛哌丁胺、LY294002和嘌呤霉素)。总之,我们通过其 ceRNA 网络确定了具有预后价值的 5-lncRNA 特征,以及五种针对 OC 的候选药物。
ABSTRACT The dysregulation of long non-coding RNAs (lncRNAs) plays a crucial role in ovarian cancer (OC). In this study, we screened out five differentially expressed lncRNAs (AC092718.4, AC138035.1, BMPR1B-DT, RNF157-AS1, and TPT1-AS1) between OC and normal ovarian based on TCGA and GTEx RNA-seq databases by using Kaplan–Meier analysis and univariate Cox, LASSO, and multivariate Cox regression. Then, a risk signature was constructed, with 1, 3, 5-year survival prediction accuracy confirmed by ROC curves, and an online survival calculator for easier clinical use. With lncRNA-microRNA-mRNA regulatory networks established, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed, suggesting the involvement of a variety of cancer-related functions and pathways. Finally, five candidate small-molecule drugs (thioridazine, trifluoperazine, loperamide, LY294002, and puromycin) were predicted by Connectivity Map. In conclusion, we identified a 5-lncRNA signature of prognostic value with its ceRNA networks, and five candidate drugs against OC.
DOI: 10.1038/nrc.2017.99
发表时间: 2018-01
期刊: Nature reviews. Cancer
影响因子: --
作者:
Anastasiadou E;Jacob LS;Slack FJ
通讯作者: Slack FJ
洛哌丁胺是一种止泻药,通过诱导细胞凋亡而具有抗肿瘤活性。
DOI: 10.1016/j.phrs.2011.11.007
发表时间: 2012-03-01
影响因子: 9.3
作者:
Gong, Xing Wen;Xu, Yu Hong;Wang, Yong Xiang
通讯作者: Wang, Yong Xiang
DOI: 10.18632/oncotarget.2063
发表时间: 2014-07-15
期刊: Oncotarget
影响因子: --
作者:
Park MS;Dong SM;Kim BR;Seo SH;Kang S;Lee EJ;Lee SH;Rho SB
通讯作者: Rho SB
DOI: 10.1016/0090-8258(92)90201-s
发表时间: 1992-07-01
影响因子: 4.7
作者:
PEREZ, RP;HANDEL, LM;HAMILTON, TC
通讯作者: HAMILTON, TC
DOI: 10.1038/nrd4140
发表时间: 2013-11
期刊: Nature reviews. Drug discovery
影响因子: --
作者:
Ling H;Fabbri M;Calin GA
通讯作者: Calin GA